These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8320904)

  • 21. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
    Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
    Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration.
    Argilés A; Kerr PG; Canaud B; Flavier JL; Mion C
    Kidney Int; 1993 Mar; 43(3):630-40. PubMed ID: 8455362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
    Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J
    Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study.
    Lezaic V; Pejanovic S; Kostic S; Pljesa S; Dimkovic N; Komadina L; Jovanovic D; Marinkovic J; Djukanovic L
    Ther Apher Dial; 2007 Apr; 11(2):121-30. PubMed ID: 17381533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lowering dialysate calcium concentration on mineral metabolism and hemodynamic parameters in hemodialysis patients.
    Alayoud A; El Kabbaj D; Benyahia M; Asseraji M; Zemraoui N
    Iran J Kidney Dis; 2015 Mar; 9(2):132-7. PubMed ID: 25851292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAPD with low calcium dialysate and calcium carbonate: results of a 24-week study.
    Honkanen E; Kala AR; Grönhagen-Riska C; Ikäheimo R
    Adv Perit Dial; 1992; 8():356-61. PubMed ID: 1361822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
    Oettinger CW; Oliver JC; Macon EJ
    J Am Soc Nephrol; 1992 Oct; 3(4):995-1001. PubMed ID: 1450373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H
    Nephron Clin Pract; 2010; 114(4):c268-76. PubMed ID: 20090369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
    Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
    Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.